IP Verse

Generics [uk] Limited opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Generics [uk] Limited

Patent Number:
EP3626270
Title:
New Use
Applicant:
NOVARTIS AG
Opposition Date:
Jul 11, 2024
Patent Number:
EP3650019
Title:
Fluticasone Furoate In The Treatment Of Copd
Applicant:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Opposition Date:
Jun 6, 2024
Patent Number:
EP3630164
Title:
Dulaglutide For The Treatment Of Chronic Kidney Disease
Applicant:
ELI LILLY AND COMPANY
Opposition Date:
May 23, 2024
Patent Number:
EP3925607
Title:
Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases
Applicant:
VERTEX PHARMACEUTICALS INCORPORATED
Opposition Date:
Mar 28, 2024
Patent Number:
EP3810201
Title:
Gip/Glp1 Agonist Compositions
Applicant:
ELI LILLY AND COMPANY
Opposition Date:
Mar 7, 2024
Patent Number:
EP3179986
Title:
Dry Powder Formulations For Inhalation
Applicant:
OTITOPIC INC.
Opposition Date:
Dec 14, 2023
Patent Number:
EP3000467
Title:
Treatment Regimen Utilizing Neratinib For Breast Cancer
Applicant:
WYETH LLC
Opposition Date:
Dec 1, 2023
Patent Number:
EP3318259
Title:
Stable Pharmaceutical Composition For Oral Administration
Applicant:
ASTELLAS PHARMA INC.
Opposition Date:
Oct 11, 2023
Patent Number:
EP2566469
Title:
Combination Therapy
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Opposition Date:
Sep 21, 2023
Patent Number:
EP3421034
Title:
Composite Capsule Preparation Containing Tadalafil And Tamsulosin And Having Improved Stability And Elution Rate
Applicant:
HANMI PHARM. CO., LTD.
Opposition Date:
Aug 16, 2023

Competitors of Generics [uk] Limited

NOVARTIS AG

ALCON RESEARCH, LTD.

ASTRAZENECA AB

Want to track Generics [uk] Limited?

Feel free to send us a message here and we will get back to you